PURPOSE: Malignant pleural mesothelioma (MPM) is a highly aggressive and symptomatic disease. We examined the relationship between health-related quality of life (HRQoL) and inflammatory markers, and the prognostic role of HRQoL in MPM patients. METHODS: MPM patients from two parallel phase II studies (thalidomide alone or thalidomide with chemotherapy) were included. HRQoL was assessed at baseline using the modified Lung Cancer Symptom Scale (LCSS). Baseline inflammatory markers and cytokines were measured. Spearman correlation was used to examine the relationship between inflammatory markers and HRQoL measures. The prognostic value of the HRQoL domains was examined using Cox proportional hazard model. RESULTS: Sixty-three patients were included: median age 61 years (range 44-79); 82% male; 77% Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 44% epithelial histology subtype. Baseline systemic symptoms of anorexia and fatigue, the summation symptoms of overall symptomatic distress, interference with normal activity and global QoL and the aggregate score of total LCSS score were all associated with elevated neutrophil-to-lymphocyte ratio, C-reactive protein and vascular endothelial growth factor levels at baseline (rho ≥ 0.25; p < 0.05). Baseline anorexia, fatigue, cough, dyspnoea, pain, overall symptomatic distress, interference with normal activity, global QoL and total LCSS score were all significantly related to survival (p < 0.05) after adjusting for established prognostic factors (age, gender, histological subtype and performance status) and treatment effect. CONCLUSIONS: In conclusion, HRQoL seems to relate to a patient's systemic inflammatory status and is associated with survival in MPM patients.
PURPOSE:Malignant pleural mesothelioma (MPM) is a highly aggressive and symptomatic disease. We examined the relationship between health-related quality of life (HRQoL) and inflammatory markers, and the prognostic role of HRQoL in MPM patients. METHODS: MPM patients from two parallel phase II studies (thalidomide alone or thalidomide with chemotherapy) were included. HRQoL was assessed at baseline using the modified Lung Cancer Symptom Scale (LCSS). Baseline inflammatory markers and cytokines were measured. Spearman correlation was used to examine the relationship between inflammatory markers and HRQoL measures. The prognostic value of the HRQoL domains was examined using Cox proportional hazard model. RESULTS: Sixty-three patients were included: median age 61 years (range 44-79); 82% male; 77% Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 44% epithelial histology subtype. Baseline systemic symptoms of anorexia and fatigue, the summation symptoms of overall symptomatic distress, interference with normal activity and global QoL and the aggregate score of total LCSS score were all associated with elevated neutrophil-to-lymphocyte ratio, C-reactive protein and vascular endothelial growth factor levels at baseline (rho ≥ 0.25; p < 0.05). Baseline anorexia, fatigue, cough, dyspnoea, pain, overall symptomatic distress, interference with normal activity, global QoL and total LCSS score were all significantly related to survival (p < 0.05) after adjusting for established prognostic factors (age, gender, histological subtype and performance status) and treatment effect. CONCLUSIONS: In conclusion, HRQoL seems to relate to a patient's systemic inflammatory status and is associated with survival in MPM patients.
Authors: Steven Chuan-Hao Kao; Rozelle Harvie; Florian Paturi; Robyn Taylor; Ross Davey; Rick Abraham; Stephen Clarke; Gavin Marx; Martin Cullen; Zoltan Kerestes; Nick Pavlakis Journal: Lung Cancer Date: 2011-07-16 Impact factor: 5.705
Authors: Steven Chuan-Hao Kao; Sonja Klebe; Douglas W Henderson; Glen Reid; Mark Chatfield; Nicola J Armstrong; Tristan D Yan; Janette Vardy; Stephen Clarke; Nico van Zandwijk; Brian McCaughan Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven Journal: Support Care Cancer Date: 2005-07-06 Impact factor: 3.603
Authors: Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke Journal: Clin Cancer Res Date: 2010-10-18 Impact factor: 12.531
Authors: Andrew Bottomley; Corneel Coens; Fabio Efficace; Rabab Gaafar; Christian Manegold; Sjaak Burgers; Mark Vincent; Catherine Legrand; Jan P van Meerbeeck Journal: J Clin Oncol Date: 2007-12-20 Impact factor: 44.544
Authors: Agata Kasprzyk; Krzysztof Bilmin; Tomira Chmielewska-Ignatowicz; Jakub Pawlikowski; Urszula Religioni; Piotr Merks Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.406
Authors: D T Arnold; C E Hooper; A Morley; P White; I D Lyburn; J Searle; M Darby; T Hall; D Hall; N M Rahman; E De Winton; A Clive; V Masani; A Dangoor; S Guglani; P Jankowska; S A Lowndes; J E Harvey; J P Braybrooke; N A Maskell Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Young Ho Yun; Young Ae Kim; Jin Ah Sim; Ae Sun Shin; Yoon Jung Chang; Jongmog Lee; Moon Soo Kim; Young Mog Shim; Jae Lll Zo Journal: BMC Cancer Date: 2016-07-20 Impact factor: 4.430